SOFTMEDX-NEW (00648) announced that all preconditions of the restructuring agreement have been fulfilled, with the first and second loan conversions completed simultaneously on November 11, 2025. Prior to the loan conversion, the company had 326 million issued shares. Following the conversion, 1.8 billion conversion shares were allotted and issued. As of the announcement date, the total number of issued shares stands at 2.126 billion.

To ensure full compliance with the public float requirements under the listing rules, the company introduced an independent placee (the "Independent Placee") and entered into an agreement with investors and the Independent Placee. Under this agreement, 1.593 billion conversion shares were allotted to investors, while 207 million conversion shares were issued to the Independent Placee.

After conducting all reasonable inquiries, the board confirms that the Independent Placee is a third party independent of the company and its connected persons (as defined under the listing rules), as well as independent of investors and their associates, and is not acting in concert with investors or HJ.